Skip to main content
Erschienen in: Wiener Medizinische Wochenschrift 21-22/2014

01.11.2014 | main topic

Epithelial ovarian cancer - more data, more questions?

verfasst von: Stefanie Aust, Dietmar Pils

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 21-22/2014

Einloggen, um Zugang zu erhalten

Summary

This review provides an overview of latest insights in epithelial ovarian cancer biology. The current understanding of the origin and the complex heterogeneity are depicted, followed by an introduction to the latest therapeutic approaches. The role of the tumor microenvironment, the high potential to disseminate within the peritoneal cavity, and new molecular biological findings are summarized.
Literatur
1.
Zurück zum Zitat Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609–15. PubMed PMID: 21720365. Pubmed Central PMCID: 3163504.CrossRef Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609–15. PubMed PMID: 21720365. Pubmed Central PMCID: 3163504.CrossRef
2.
Zurück zum Zitat Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30. PubMed PMID: 23335087.PubMedCrossRef Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30. PubMed PMID: 23335087.PubMedCrossRef
3.
Zurück zum Zitat Goff BA, Mandel LS, Drescher CW, Urban N, Gough S, Schurman KM, et al. Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer. 2007;109(2):221–7. PubMed PMID: 17154394.PubMedCrossRef Goff BA, Mandel LS, Drescher CW, Urban N, Gough S, Schurman KM, et al. Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer. 2007;109(2):221–7. PubMed PMID: 17154394.PubMedCrossRef
4.
Zurück zum Zitat Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, et al. Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006;95(Suppl. 1):S161–92. PubMed PMID: 17161157. Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, et al. Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006;95(Suppl. 1):S161–92. PubMed PMID: 17161157.
5.
Zurück zum Zitat Prat J. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2014;124(1):1–5. PubMed PMID: 24219974.PubMedCrossRef Prat J. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2014;124(1):1–5. PubMed PMID: 24219974.PubMedCrossRef
6.
Zurück zum Zitat Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH, et al. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol. 2001;195(4):451–6. PubMed PMID: 11745677.PubMedCrossRef Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH, et al. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol. 2001;195(4):451–6. PubMed PMID: 11745677.PubMedCrossRef
7.
Zurück zum Zitat Bahar-Shany K, Brand H, Sapoznik S, Jacob-Hirsch J, Yung Y, Korach J, et al. Exposure of fallopian tube epithelium to follicular fluid mimics carcinogenic changes in precursor lesions of serous papillary carcinoma. Gynecol Oncol. 2014;132(2):322–7. PubMed PMID: 24355484.PubMedCrossRef Bahar-Shany K, Brand H, Sapoznik S, Jacob-Hirsch J, Yung Y, Korach J, et al. Exposure of fallopian tube epithelium to follicular fluid mimics carcinogenic changes in precursor lesions of serous papillary carcinoma. Gynecol Oncol. 2014;132(2):322–7. PubMed PMID: 24355484.PubMedCrossRef
8.
Zurück zum Zitat Blaustein A. Peritoneal mesothelium and ovarian surface cells–shared characteristics. Int J Gynecol Pathol. 1984;3(4):361–75. PubMed PMID: 6511162.PubMed Blaustein A. Peritoneal mesothelium and ovarian surface cells–shared characteristics. Int J Gynecol Pathol. 1984;3(4):361–75. PubMed PMID: 6511162.PubMed
9.
Zurück zum Zitat Sundfeldt K, Piontkewitz Y, Ivarsson K, Nilsson O, Hellberg P, Brannstrom M, et al. E-cadherin expression in human epithelial ovarian cancer and normal ovary. Int J Cancer. 1997;74(3):275–80. PubMed PMID: 9221804.PubMedCrossRef Sundfeldt K, Piontkewitz Y, Ivarsson K, Nilsson O, Hellberg P, Brannstrom M, et al. E-cadherin expression in human epithelial ovarian cancer and normal ovary. Int J Cancer. 1997;74(3):275–80. PubMed PMID: 9221804.PubMedCrossRef
10.
Zurück zum Zitat Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, Saleemuddin A, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol. 2007;211(1):26–35. PubMed PMID: 17117391.PubMedCrossRef Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, Saleemuddin A, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol. 2007;211(1):26–35. PubMed PMID: 17117391.PubMedCrossRef
11.
Zurück zum Zitat Sehdev AS, Kurman RJ, Kuhn E, Shih Ie M. Serous tubal intraepithelial carcinoma upregulates markers associated with high-grade serous carcinomas including Rsf-1 (HBXAP), cyclin E and fatty acid synthase. Mod Pathol. 2010;23(6):844–55. PubMed PMID: 20228782. Pubmed Central PMCID: 2879438.PubMedCentralPubMedCrossRef Sehdev AS, Kurman RJ, Kuhn E, Shih Ie M. Serous tubal intraepithelial carcinoma upregulates markers associated with high-grade serous carcinomas including Rsf-1 (HBXAP), cyclin E and fatty acid synthase. Mod Pathol. 2010;23(6):844–55. PubMed PMID: 20228782. Pubmed Central PMCID: 2879438.PubMedCentralPubMedCrossRef
12.
Zurück zum Zitat Erickson BK, Conner MG, Landen CN, Jr. The role of the fallopian tube in the origin of ovarian cancer. Am J Obstet Gynecol. 2013;209(5):409–14. PubMed PMID: 23583217. Pubmed Central PMCID: 3937451. Erickson BK, Conner MG, Landen CN, Jr. The role of the fallopian tube in the origin of ovarian cancer. Am J Obstet Gynecol. 2013;209(5):409–14. PubMed PMID: 23583217. Pubmed Central PMCID: 3937451.
13.
Zurück zum Zitat McCluggage WG. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology. 2011;43(5):420–32. PubMed PMID: 21716157. McCluggage WG. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology. 2011;43(5):420–32. PubMed PMID: 21716157.
14.
Zurück zum Zitat Shih Ie M, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004;164(5):1511–8. PubMed PMID: 15111296. Pubmed Central PMCID: 1615664. Shih Ie M, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004;164(5):1511–8. PubMed PMID: 15111296. Pubmed Central PMCID: 1615664.
15.
Zurück zum Zitat Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res. 2008;14(16):5198–208. PubMed PMID: 18698038. Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res. 2008;14(16):5198–208. PubMed PMID: 18698038.
16.
Zurück zum Zitat Yoshihara K, Tajima A, Komata D, Yamamoto T, Kodama S, Fujiwara H, et al. Gene expression profiling of advanced-stage serous ovarian cancers distinguishes novel subclasses and implicates ZEB2 in tumor progression and prognosis. Cancer Sci. 2009;100(8):1421–8. PubMed PMID: 19486012. Yoshihara K, Tajima A, Komata D, Yamamoto T, Kodama S, Fujiwara H, et al. Gene expression profiling of advanced-stage serous ovarian cancers distinguishes novel subclasses and implicates ZEB2 in tumor progression and prognosis. Cancer Sci. 2009;100(8):1421–8. PubMed PMID: 19486012.
17.
Zurück zum Zitat Pils D, Hager G, Tong D, Aust S, Heinze G, Kohl M, et al. Validating the impact of a molecular subtype in ovarian cancer on outcomes: a study of the OVCAD Consortium. Cancer Sci. 2012;103(7):1334–41. PubMed PMID: 22497737. Pils D, Hager G, Tong D, Aust S, Heinze G, Kohl M, et al. Validating the impact of a molecular subtype in ovarian cancer on outcomes: a study of the OVCAD Consortium. Cancer Sci. 2012;103(7):1334–41. PubMed PMID: 22497737.
18.
Zurück zum Zitat Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225–49. PubMed PMID: 19474385. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225–49. PubMed PMID: 19474385.
19.
Zurück zum Zitat Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363(10):943–53. PubMed PMID: 20818904. Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363(10):943–53. PubMed PMID: 20818904.
20.
Zurück zum Zitat Polterauer S, Vergote I, Concin N, Braicu I, Chekerov R, Mahner S, et al. Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data. Int J Gynecol Cancer. 2012;22(3):380–5. PubMed PMID: 22266934. Polterauer S, Vergote I, Concin N, Braicu I, Chekerov R, Mahner S, et al. Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data. Int J Gynecol Cancer. 2012;22(3):380–5. PubMed PMID: 22266934.
21.
Zurück zum Zitat Harter P, Mahner S, Hilpert F, Runnebaum I, Ortmann O, Mustea A, et al. Statement by the Kommission OVAR of the AGO Study Group on the Use of HIPEC (Hyperthermic Intraperitoneal Chemotherapy) to Treat Primary and Recurrent Ovarian Cancer. Geburtshilfe Frauenheilkd. 2013;73(3):221–3. PubMed PMID: 24771913. Harter P, Mahner S, Hilpert F, Runnebaum I, Ortmann O, Mustea A, et al. Statement by the Kommission OVAR of the AGO Study Group on the Use of HIPEC (Hyperthermic Intraperitoneal Chemotherapy) to Treat Primary and Recurrent Ovarian Cancer. Geburtshilfe Frauenheilkd. 2013;73(3):221–3. PubMed PMID: 24771913.
22.
Zurück zum Zitat Siddiqui GK, Maclean AB, Elmasry K, Wong te Fong A, Morris RW, Rashid M, et al. Immunohistochemical expression of VEGF predicts response to platinum based chemotherapy in patients with epithelial ovarian cancer. Angiogenesis. 2011;14(2):155–61. PubMed PMID: 21221762. Siddiqui GK, Maclean AB, Elmasry K, Wong te Fong A, Morris RW, Rashid M, et al. Immunohistochemical expression of VEGF predicts response to platinum based chemotherapy in patients with epithelial ovarian cancer. Angiogenesis. 2011;14(2):155–61. PubMed PMID: 21221762.
23.
Zurück zum Zitat Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473–83. PubMed PMID: 22204724. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473–83. PubMed PMID: 22204724.
24.
Zurück zum Zitat Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484–96. PubMed PMID: 22204725. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484–96. PubMed PMID: 22204725.
25.
Zurück zum Zitat Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285(21):1182–6. PubMed PMID: 4938153. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285(21):1182–6. PubMed PMID: 4938153.
26.
Zurück zum Zitat Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348(3):203–13. PubMed PMID: 12529460. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348(3):203–13. PubMed PMID: 12529460.
27.
Zurück zum Zitat Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960–4. PubMed PMID: 17008531. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960–4. PubMed PMID: 17008531.
28.
Zurück zum Zitat Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol. 2007;25(18):2586–93. PubMed PMID: 17577038. Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol. 2007;25(18):2586–93. PubMed PMID: 17577038.
29.
Zurück zum Zitat Gooden MJ, de Bock GH, Leffers N, Daemen T, Nijman HW. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer. 2011;105(1):93–103. PubMed PMID: 21629244. Pubmed Central PMCID: 3137407. Gooden MJ, de Bock GH, Leffers N, Daemen T, Nijman HW. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer. 2011;105(1):93–103. PubMed PMID: 21629244. Pubmed Central PMCID: 3137407.
30.
Zurück zum Zitat Nosho K, Baba Y, Tanaka N, Shima K, Hayashi M, Meyerhardt JA, et al. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol. 2010;222(4):350–66. PubMed PMID: 20927778. Pubmed Central PMCID: 3033700. Nosho K, Baba Y, Tanaka N, Shima K, Hayashi M, Meyerhardt JA, et al. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol. 2010;222(4):350–66. PubMed PMID: 20927778. Pubmed Central PMCID: 3033700.
31.
Zurück zum Zitat Sorbye SW, Kilvaer T, Valkov A, Donnem T, Smeland E, Al-Shibli K, et al. Prognostic impact of lymphocytes in soft tissue sarcomas. PLoS One. 2011;6(1):e14611. PubMed PMID: 21298041. Pubmed Central PMCID: 3029277. Sorbye SW, Kilvaer T, Valkov A, Donnem T, Smeland E, Al-Shibli K, et al. Prognostic impact of lymphocytes in soft tissue sarcomas. PLoS One. 2011;6(1):e14611. PubMed PMID: 21298041. Pubmed Central PMCID: 3029277.
32.
Zurück zum Zitat Wakabayashi O, Yamazaki K, Oizumi S, Hommura F, Kinoshita I, Ogura S, et al. CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers. Cancer Sci. 2003;94(11):1003–9. PubMed PMID: 14611679. Wakabayashi O, Yamazaki K, Oizumi S, Hommura F, Kinoshita I, Ogura S, et al. CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers. Cancer Sci. 2003;94(11):1003–9. PubMed PMID: 14611679.
33.
Zurück zum Zitat Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 2011;29(15):1949–55. PubMed PMID: 21483002. Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 2011;29(15):1949–55. PubMed PMID: 21483002.
34.
Zurück zum Zitat Liu F, Lang R, Zhao J, Zhang X, Pringle GA, Fan Y, et al. CD8(+) cytotoxic T cell and FOXP3(+) regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes. Breast Cancer Res Treat. 2011;130(2):645–55. PubMed PMID: 21717105. Liu F, Lang R, Zhao J, Zhang X, Pringle GA, Fan Y, et al. CD8(+) cytotoxic T cell and FOXP3(+) regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes. Breast Cancer Res Treat. 2011;130(2):645–55. PubMed PMID: 21717105.
35.
Zurück zum Zitat Matkowski R, Gisterek I, Halon A, Lacko A, Szewczyk K, Staszek U, et al. The prognostic role of tumor-infiltrating CD4 and CD8 T lymphocytes in breast cancer. Anticancer Res. 2009;29(7):2445–51. PubMed PMID: 19596912. Matkowski R, Gisterek I, Halon A, Lacko A, Szewczyk K, Staszek U, et al. The prognostic role of tumor-infiltrating CD4 and CD8 T lymphocytes in breast cancer. Anticancer Res. 2009;29(7):2445–51. PubMed PMID: 19596912.
36.
Zurück zum Zitat Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A. 2005;102(51):18538–43. PubMed PMID: 16344461. Pubmed Central PMCID: 1311741. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A. 2005;102(51):18538–43. PubMed PMID: 16344461. Pubmed Central PMCID: 1311741.
37.
Zurück zum Zitat Clarke B, Tinker AV, Lee CH, Subramanian S, van de Rijn M, Turbin D, et al. Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol. 2009;22(3):393–402. PubMed PMID: 19060844. Clarke B, Tinker AV, Lee CH, Subramanian S, van de Rijn M, Turbin D, et al. Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol. 2009;22(3):393–402. PubMed PMID: 19060844.
38.
Zurück zum Zitat Shah CA, Allison KH, Garcia RL, Gray HJ, Goff BA, Swisher EM. Intratumoral T cells, tumor-associated macrophages, and regulatory T cells: association with p53 mutations, circulating tumor DNA and survival in women with ovarian cancer. Gynecol Oncol. 2008;109(2):215–9. PubMed PMID: 18314181. Shah CA, Allison KH, Garcia RL, Gray HJ, Goff BA, Swisher EM. Intratumoral T cells, tumor-associated macrophages, and regulatory T cells: association with p53 mutations, circulating tumor DNA and survival in women with ovarian cancer. Gynecol Oncol. 2008;109(2):215–9. PubMed PMID: 18314181.
39.
Zurück zum Zitat Leffers N, Gooden MJ, de Jong RA, Hoogeboom BN, ten Hoor KA, Hollema H, et al. Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother. 2009;58(3):449–59. PubMed PMID: 18791714. Leffers N, Gooden MJ, de Jong RA, Hoogeboom BN, ten Hoor KA, Hollema H, et al. Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother. 2009;58(3):449–59. PubMed PMID: 18791714.
40.
Zurück zum Zitat Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A. 2007;104(9):3360–5. PubMed PMID: 17360651. Pubmed Central PMCID: 1805580. Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A. 2007;104(9):3360–5. PubMed PMID: 17360651. Pubmed Central PMCID: 1805580.
41.
Zurück zum Zitat Milne K, Kobel M, Kalloger SE, Barnes RO, Gao D, Gilks CB, et al. Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One. 2009;4(7):e6412. PubMed PMID: 19641607. Pubmed Central PMCID: 2712762. Milne K, Kobel M, Kalloger SE, Barnes RO, Gao D, Gilks CB, et al. Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One. 2009;4(7):e6412. PubMed PMID: 19641607. Pubmed Central PMCID: 2712762.
42.
Zurück zum Zitat Bachmayr-Heyda A, Aust S, Heinze G, Polterauer S, Grimm C, Braicu EI, et al. Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients—a study of the OVCAD consortium. BMC Cancer. 2013;13:422. PubMed PMID: 24044611. Pubmed Central PMCID: 3848589. Bachmayr-Heyda A, Aust S, Heinze G, Polterauer S, Grimm C, Braicu EI, et al. Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients—a study of the OVCAD consortium. BMC Cancer. 2013;13:422. PubMed PMID: 24044611. Pubmed Central PMCID: 3848589.
43.
Zurück zum Zitat Aust S, Bachmayr-Heyda A, Pils D, Zhao L, Tong W, Berger A, et al. Determination of tumor-infiltrating CD8+ lymphocytes in human ovarian cancer. Int J Gynecol Pathol. 2013;32(3):269–76. PubMed PMID: 23518910. Aust S, Bachmayr-Heyda A, Pils D, Zhao L, Tong W, Berger A, et al. Determination of tumor-infiltrating CD8+ lymphocytes in human ovarian cancer. Int J Gynecol Pathol. 2013;32(3):269–76. PubMed PMID: 23518910.
44.
Zurück zum Zitat Aust S, Bachmayr-Heyda A, Pateisky P, Tong D, Darb-Esfahani S, Denkert C, et al. Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer—a study of the OVCAD consortium. Mol Cancer. 2012;11:69. PubMed PMID: 22978347. Pubmed Central PMCID: 3533746. Aust S, Bachmayr-Heyda A, Pateisky P, Tong D, Darb-Esfahani S, Denkert C, et al. Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer—a study of the OVCAD consortium. Mol Cancer. 2012;11:69. PubMed PMID: 22978347. Pubmed Central PMCID: 3533746.
45.
Zurück zum Zitat Pils D, Bachmayr-Heyda A, Auer K, Svoboda M, Auner V, Hager G, et al. Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients—a study of the OVCAD consortium. Eur J Cancer. 2014;50(1):99–110. PubMed PMID: 24176298. Pils D, Bachmayr-Heyda A, Auer K, Svoboda M, Auner V, Hager G, et al. Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients—a study of the OVCAD consortium. Eur J Cancer. 2014;50(1):99–110. PubMed PMID: 24176298.
46.
Zurück zum Zitat Aust S, Auer K, Bachmayr-Heyda A, Denkert C, Sehouli J, Braicu I, et al. Ambivalent role of pFAK-Y397 in serous ovarian cancer—a study of the OVCAD consortium. Mol Cancer. 2014;13:67. PubMed PMID: 24655477. Pubmed Central PMCID: 3998046. Aust S, Auer K, Bachmayr-Heyda A, Denkert C, Sehouli J, Braicu I, et al. Ambivalent role of pFAK-Y397 in serous ovarian cancer—a study of the OVCAD consortium. Mol Cancer. 2014;13:67. PubMed PMID: 24655477. Pubmed Central PMCID: 3998046.
47.
Zurück zum Zitat O’Toole SA, Selinger CI, Millar EK, Lum T, Beith JM. Molecular assays in breast cancer pathology. Pathology. 2011;43(2):116–27. PubMed PMID: 21233672. O’Toole SA, Selinger CI, Millar EK, Lum T, Beith JM. Molecular assays in breast cancer pathology. Pathology. 2011;43(2):116–27. PubMed PMID: 21233672.
48.
Zurück zum Zitat Ween MP, Lokman NA, Hoffmann P, Rodgers RJ, Ricciardelli C, Oehler MK. Transforming growth factor-beta-induced protein secreted by peritoneal cells increases the metastatic potential of ovarian cancer cells. Int J Cancer. 2011;128(7):1570–84. PubMed PMID: 20521251. Ween MP, Lokman NA, Hoffmann P, Rodgers RJ, Ricciardelli C, Oehler MK. Transforming growth factor-beta-induced protein secreted by peritoneal cells increases the metastatic potential of ovarian cancer cells. Int J Cancer. 2011;128(7):1570–84. PubMed PMID: 20521251.
49.
Zurück zum Zitat Said NA, Najwer I, Socha MJ, Fulton DJ, Mok SC, Motamed K. SPARC inhibits LPA-mediated mesothelial-ovarian cancer cell crosstalk. Neoplasia. 2007;9(1):23–35. PubMed PMID: 17325741. Pubmed Central PMCID: 1803033. Said NA, Najwer I, Socha MJ, Fulton DJ, Mok SC, Motamed K. SPARC inhibits LPA-mediated mesothelial-ovarian cancer cell crosstalk. Neoplasia. 2007;9(1):23–35. PubMed PMID: 17325741. Pubmed Central PMCID: 1803033.
Metadaten
Titel
Epithelial ovarian cancer - more data, more questions?
verfasst von
Stefanie Aust
Dietmar Pils
Publikationsdatum
01.11.2014
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 21-22/2014
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-014-0323-8

Weitere Artikel der Ausgabe 21-22/2014

Wiener Medizinische Wochenschrift 21-22/2014 Zur Ausgabe